Episodes

  • Advancing MOGAD Care

    Advancing MOGAD Care
    Jun 23 2026
    Episode Description: What do the latest METEOROID trial results mean for neurologists treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)? Michael Levy, MD, Massachusetts General Hospital, Boston, MA, discusses relapse prevention, diagnostic challenges, and the future of MOGAD management with Peter Sguigna, MD, UT Southwestern Medical Center, Dallas, TX.
    Show More Show Less
    10 mins
  • Generalized Myasthenia Gravis: Inside the MINT Trial and CD19 B-Cell Therapy Advances

    Generalized Myasthenia Gravis: Inside the MINT Trial and CD19 B-Cell Therapy Advances
    May 15 2026
    Richard J. Nowak, MD, MS, Associate Professor of Neurology, Yale School of Medicine, Yale University, New Haven, CT and global principal investigator of the Myasthenia Gravis Inebilizumab Trial (MINT), discusses the phase 3 results, highlighting the safety and efficacy of CD19-targeted B-cell therapy for individuals with generalized myasthenia gravis and its impact on outcomes and steroid reduction in real-world practice. Additional details about MINT may be found in the following publication: The New England Journal of Medicine. For more information on the medication discussed in this episode, please refer to the Full Prescribing Information provided by Amgen, last updated 12/2025.
    Show More Show Less
    16 mins
  • The Use of Intracranial Vessel Wall MRI for the Diagnosis of Vasculitis

    The Use of Intracranial Vessel Wall MRI for the Diagnosis of Vasculitis
    Oct 29 2025
    Jae W. Song, MD, MS, Associate Professor of Radiology at the University of Pennsylvania, Philadelphia, PA, discusses the diagnostic value of intracranial vessel wall MRI for vasculitis, as well as when clinicians should order this imaging technique and the challenges that may arise.
    Show More Show Less
    8 mins
  • Ocrevus Treatment in Pregnant and Lactating Women with Multiple Sclerosis

    Ocrevus Treatment in Pregnant and Lactating Women with Multiple Sclerosis
    Oct 29 2025
    Riley Bove, MD, UCSF School of Medicine, San Francisco, CA details results from the MINORE and SOPRANINO studies examining Ocrevus treatment in pregnant and lactating women with multiple sclerosis.
    Show More Show Less
    14 mins
  • New Guidelines for the Assessment of Traumatic Brain Injury

    New Guidelines for the Assessment of Traumatic Brain Injury
    May 7 2025
    Beth McQuiston, MD, RD, Medical Director, Abbott, Abbott Park, IL, and David Okonkwo, MD, PhD, Professor of Neurological Surgery, University of Pittsburgh, Pittsburg, PA, describe some of the important updates to guidelines for the assessment of traumatic brain injury, including biomarker testing.
    Show More Show Less
    21 mins
  • The Impact of High Efficacy DMTs on Paramagnetic Rim Lesions

    The Impact of High Efficacy DMTs on Paramagnetic Rim Lesions
    Mar 22 2025
    Jack Reeves, PhD, researcher at the University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, discusses results of a study which demonstrated high efficacy disease-modifying therapies may help prevent the development of paramagnetic rim lesions and slow the progression of multiple sclerosis.
    Show More Show Less
    14 mins
  • Proposed Hospital Standards for Parkinson Disease Care Aim to Avoid Preventable Harm

    Proposed Hospital Standards for Parkinson Disease Care Aim to Avoid Preventable Harm
    Mar 14 2025
    Preventable harm is a serious concern for patients with Parkinson disease who receive care in the hospital setting, even when admitted for reasons other than their diagnosis. Peter Pronovost, MD, PhD, FCCM, Chief Quality and Transformation Officer at University Hospitals Cleveland Medical Center, Cleveland, OH, discusses his work with the Parkinson’s Foundation developing new hospital care standards for reducing medication mismanagement and improper or insufficient care.
    Show More Show Less
    15 mins
  • Promising Results for Investigational Antisense Oligonucleotide Treatment for Dravet Syndrome

    Promising Results for Investigational Antisense Oligonucleotide Treatment for Dravet Syndrome
    Jan 22 2025
    Joseph Sullivan, MD, Professor, UCSF School of Medicine, San Francisco, CA, describes encouraging results from the SWALLOWTAIL and LONGWING studies of an investigational treatment for individuals with Dravet syndrome, including outcomes related to seizure frequency, cognition, and behavior.
    Show More Show Less
    18 mins